|
|
||||||||||
|
J Am Coll Cardiol, 2000; 35:284-291 © 2000 by the American College of Cardiology Foundation |

* First Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
Department of Clinical Laboratory Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
Manuscript received February 8, 1999; revised manuscript received August 24, 1999, accepted October 18, 1999.
Reprint requests and correspondence: Dr. Yukihito Higashi, Hiroshima University School of Medicine, First Department of Internal Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
yhigashi{at}mcai.med.hiroshima-u.ac.jp
OBJECTIVES
The purpose of this study was to compare the effect of different antihypertensive agents, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and diuretic agents on endothelial function.
BACKGROUND
Endothelial dysfunction is a component of essential hypertension, and various antihypertensive drugs may be able to restore normal function.
METHODS
Forearm blood flow (FBF) was measured in 296 patients with essential hypertension, including 46 untreated subjects using strain-gauge plethysmography during reactive hyperemia and after sublingual administration of nitroglycerin (NTG). Forty-seven normotensive subjects were similarly evaluated as control subjects.
RESULTS
The FBF during reactive hyperemia in the 296 hypertensive patients was significantly less than that in age-matched normotensive subjects. The increase in FBF after administration of sublingual NTG was similar in both groups. Systolic and diastolic blood pressures and forearm vascular resistance were greater in the untreated group than in the four treated groups and did not differ with respect to the antihypertensive agent used. The maximal FBF response from reactive hyperemia was significantly greater in the ACE inhibitortreated group than in the group treated with calcium antagonists, beta-blockers, diuretic agents, or nothing (40.5 ± 5.2 vs. 32.9 ± 5.8, 34.0 ± 5.6, 32.1 ± 5.9, and 31.9 ± 5.8 ml/min per 100 ml tissue, p < 0.05, respectively). Reactive hyperemia was similar in the calcium antagonist, beta-blocker, diuretic and untreated groups, and changes in FBF after sublingual NTG administration were similar in all groups. The infusion of NG-monomethyl-L-arginine, a nitric oxide (NO) synthase inhibitor, abolished the enhancement of reactive hyperemia in hypertensive patients treated with ACE inhibitors.
CONCLUSIONS
These findings suggest that ACE inhibitors augment reactive hyperemia, an index of endothelium-dependent vasorelaxation, in patients with essential hypertension. This augmentation may be due to increases in NO.
| ||||||||||||||||
This article has been cited by other articles:
![]() |
R. E. Schmieder, C. Delles, A. Mimran, J. P. Fauvel, and L. M. Ruilope Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1351 - 1356. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Ahimastos, A. Lawler, C. M. Reid, P. A. Blombery, and B. A. Kingwell Brief Communication: Ramipril Markedly Improves Walking Ability in Patients with Peripheral Arterial Disease: A Randomized Trial Ann Intern Med, May 2, 2006; 144(9): 660 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Erzen, P. Gradisek, P. Poredos, and M. Sabovic Treatment of Essential Arterial Hypertension with Enalapril Does Not Result in Normalization of Endothelial Dysfunction of the Conduit Arteries Angiology, March 1, 2006; 57(2): 187 - 192. [Abstract] [PDF] |
||||
![]() |
G. Dell'Omo, G. Penno, S. Del Prato, and R. Pedrinelli Chlorthalidone Improves Endothelial-Mediated Vascular Responses in Hypertension Complicated by Nondiabetic Metabolic Syndrome Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4): 265 - 272. [Abstract] [PDF] |
||||
![]() |
D Tousoulis, C Antoniades, E Bosinakou, M Kotsopoulou, C Tsioufis, C Tentolouris, A Trikas, C Pitsavos, and C Stefanadis Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure Heart, January 1, 2005; 91(1): 27 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Harris and K. A. Matthews Interactions Between Autonomic Nervous System Activity and Endothelial Function: A Model for the Development of Cardiovascular Disease Psychosom Med, March 1, 2004; 66(2): 153 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Widlansky, N. Gokce, J. F. Keaney Jr, and J. A. Vita The clinical implications of endothelial dysfunction J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1149 - 1160. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tousoulis, C. Antoniades, C. Tountas, E. Bosinakou, M. Kotsopoulou, P. Toutouzas, and C. Stefanadis Vitamin C Affects Thrombosis/ Fibrinolysis System and Reactive Hyperemia in Patients With Type 2 Diabetes and Coronary Artery Disease Diabetes Care, October 1, 2003; 26(10): 2749 - 2753. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yavuz, M. Koc, A. Toprak, I. Akp{iota}nar, A. Velioglu, O. Deyneli, G. Haklar, and S. Akalln Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 197 - 203. [Abstract] [PDF] |
||||
![]() |
M. Kimura, Y. Higashi, K. Hara, K. Noma, S. Sasaki, K. Nakagawa, C. Goto, T. Oshima, M. Yoshizumi, and K. Chayama PDE5 Inhibitor Sildenafil Citrate Augments Endothelium-Dependent Vasodilation in Smokers Hypertension, May 1, 2003; 41(5): 1106 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Enseleit, T.F. Luscher, and F. Ruschitzka Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A31 - A36. [Abstract] [PDF] |
||||
![]() |
Y. Higashi, S. Sasaki, K. Nakagawa, H. Matsuura, T. Oshima, and K. Chayama Endothelial Function and Oxidative Stress in Renovascular Hypertension N. Engl. J. Med., June 20, 2002; 346(25): 1954 - 1962. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Higashi, S. Sasaki, K. Nakagawa, M. Kimura, S. Sasaki, K. Noma, H. Matsuura, K. Hara, C. Goto, T. Oshima, et al. Excess Norepinephrine Impairs Both Endothelium-Dependent and -Independent Vasodilation in Patients With Pheochromocytoma Hypertension, February 1, 2002; 39(2): 513 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Chillon and G. L. Baumbach Effects of an Angiotensin-Converting Enzyme Inhibitor and a {beta}-Blocker on Cerebral Arteriolar Dilatation in Hypertensive Rats Hypertension, June 1, 2001; 37(6): 1388 - 1393. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Higashi, S. Sasaki, K. Nakagawa, H. Matsuura, G. Kajiyama, and T. Oshima Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function J. Am. Coll. Cardiol., March 1, 2001; 37(3): 863 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Shaw, J. P. F. Chin-Dusting, B. A. Kingwell, and A. M. Dart Diurnal Variation in Endothelium-Dependent Vasodilatation Is Not Apparent in Coronary Artery Disease Circulation, February 13, 2001; 103(6): 806 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Duffy, N. Gokce, M. Holbrook, L. M. Hunter, E. S. Biegelsen, A. Huang, J. F. Keaney Jr., and J. A. Vita Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H528 - H534. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Higashi, M. Sanada, S. Sasaki, K. Nakagawa, C. Goto, H. Matsuura, K. Ohama, K. Chayama, and T. Oshima Effect of Estrogen Replacement Therapy on Endothelial Function in Peripheral Resistance Arteries in Normotensive and Hypertensive Postmenopausal Women Hypertension, February 1, 2001; 37(2): 651 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. O'Keefe, M. Wetzel, R. R. Moe, K. Brosnahan, and C. J. Lavie Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J. Am. Coll. Cardiol., January 1, 2001; 37(1): 1 - 8. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |